SCHEMBL3451335

SCHEMBL3451335

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2NCc2ccncc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 2/20 0.43
CSNK2A1 P68400 2/20 0.42
AXL P30530 1/20 0.41
STK17B O94768 1/20 0.41
NTRK1 P04629 3/20 0.41
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ALK Q9UM73 1/20 0.40
PTK2 Q05397 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
JAK3 P52333 1/20 0.40
SYK P43405 2/20 0.40
GAA P10253 1/20 0.39
NAMPT P43490 1/20 0.39
KMT2A Q03164 1/20 0.39
FGFR1 P11362 2/20 0.39
KDR P35968 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448546 0.92 STK17A (0.46) STK17ACSNK2A1AXLSTK17BNTRK1
SCHEMBL3450074 0.92 CSNK2A1 (0.51) STK17ACSNK2A1AXLNTRK1EGFR
SCHEMBL3448109 0.89 JAK3 (0.46) STK17AAXLNTRK1EGFRERBB2
SCHEMBL3448587 0.89 STK17A (0.50) STK17ACSNK2A1AXLSTK17BEGFR
SCHEMBL13311087 0.89 CSNK2A1 (0.51) STK17ACSNK2A1AXLSTK17BNTRK1
SCHEMBL3448098 0.89 CSNK2A1 (0.49) STK17ACSNK2A1STK17BEGFRPTK2
SCHEMBL3448849 0.88 SYK (0.49) STK17ACSNK2A1AXLSTK17BEGFR
SCHEMBL3449761 0.88 STK17A (0.42) STK17ACSNK2A1AXLSTK17BEGFR
SCHEMBL3451827 0.87 CSNK2A1 (0.49) STK17ACSNK2A1AXLSTK17BEGFR
SCHEMBL3449942 0.86 MAP3K8 (0.43) STK17ACSNK2A1AXLSTK17BNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD STK17A 1984/4885CSNK2A1 1858/4885AXL 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.